How Social Vulnerability Changes the Case for Metabolic Surgery in Type 2 Diabetes

Social determinants of health are increasingly recognized as critical drivers of outcomes in chronic disease management, particularly for patients with type 2 diabetes and obesity. In this Q&A, Mary Elizabeth Patti, MD discusses new insights from a randomized clinical trial examining how social vulnerability influences treatment outcomes with medical and lifestyle therapy versus metabolic surgery.

Key Highlights

• Metabolic surgery outperformed medical and lifestyle therapy regardless of social vulnerability, demonstrating its effectiveness even among patients facing significant socioeconomic barriers.
• Social determinants of health meaningfully influence diabetes outcomes, emphasizing the need for clinicians to assess social vulnerability as part of individualized treatment planning.
• Early, equitable discussions about surgery are essential, as metabolic surgery offers a durable, safe option that may overcome barriers related to medication access, adherence, and cost for socially vulnerable patients.

Consultant360: What clinical question motivated this analysis of social vulnerability within the ARMMS-T2D trials, and why is it especially relevant for clinicians managing type 2 diabetes today?

Dr. Patti: Well, I think it's well recognized now by most clinicians that social determinants of health are critical factors in the overall health of our patients, and social vulnerability needs to be included as a component of individualized care plans. This is especially true for patients who are experiencing type 2 diabetes and coexisting obesity. As we were conducting this particular randomized trial, the ARMMS-T2D trial, I was seeing participants for their annual follow-up visits, and what really struck me in my conversations with patients was the profound impact that life stressors have on their overall diabetes control.  I think this was particularly prominent in the setting of a research study, because we were following these patients over time, and I had more time to interact with them and discuss social factors in their lives. This raised the question of whether the social vulnerability effects were, in fact, different in those randomized to either medical and lifestyle therapy or metabolic surgery for type 2 diabetes and obesity. Based on this, we decided to assess the impact of social vulnerability on outcomes in either of the 2 treatment arms in this randomized study.

Consultant360: Were you surprised that social vulnerability did not significantly modify the comparative benefit of surgery, and what do you think explains this finding in a randomized setting?

Dr. Patti: We anticipated that vulnerability would have a greater effect in the medical and lifestyle group than in the surgical group, and in fact, that's what we observed. However, the differences in the relative efficacy of medical vs. surgical therapy between the high- and low-vulnerability groups were not statistically significant. This reinforced the importance of social vulnerability as an important factor when individualizing treatment plans. Overall, these results show us that surgery is more effective than medical and lifestyle intervention, even when social vulnerability is high. The primary message is that the surgical approach continues to outperform medical therapy.

Consultant360: When counseling patients with type 2 diabetes and obesity who face socioeconomic barriers, how should clinicians incorporate these findings into shared decision-making about surgery versus medical therapy?

Dr. Patti: Well, I would encourage clinicians to have a conversation about long-term strategies for management of type 2 diabetes, prevention of complications, and maintenance of health.  This should occur soon after diagnosis. As you know, type 2 diabetes is a progressive disease, with progressive loss of beta cell function over time associated with loss of glycemic control.  Since the benefits of surgical approaches are greatest during early stages of diabetes, during the first few years, this is an important “window of action” for education and decision-making regarding choice of medical/lifestyle management, metabolic surgery, or a combination of approaches.  That conversation should focus on concerns that despite the high success rate of the new medications for diabetes, many patients are unable to tolerate the medications due to side effects, or they are unable to continue the medications because of a lack of insurance coverage or high copay or self-pay costs that are not within reach for an individual patient.  Surgery is an alternative that engages similar intestinally derived mechanisms as GLP1-based medications, yet is more potent and more durable. Moreover, a number of studies have shown that surgery has improved efficacy for diabetes, increased likelihood of diabetes remission, reduced need for medications, reduced complications, and even reduced mortality. The risks of surgery are quite low, comparable to those of having one's gallbladder removed. It's really an effective, durable, and safe option for those with type 2 diabetes. Of course, patients may decide that is not what is best for them, but surgical options should be reconsidered, especially if glycemic and health goals are not being achieved with medical therapy. A combination of both is sometimes appropriate. The bottom line is that patients should be educated about the comparative benefits of surgery vs. medical therapy, and the patient’s health and preferences should be incorporated into an individualized discussion.

Consultant360: For clinicians who may hesitate to refer socially vulnerable patients for bariatric surgery, what message does this study offer regarding equity and access to care?

Dr. Patti: I think it is important to let patients know that surgery is an option that is effective and safe for everyone.  Surgery may provide particular benefits for individual patients who are worried about their ability to manage the long-standing challenges of diabetes care, including the need to be active and exercise, to make specific food choices, and to juggle multiple medications and their costs.  While surgery is not an easy option either, improvements in glucose control, remission, or reduced need for medications (including insulin) can be advantageous, especially for patinets also experiencing with high social vulnerability. The message is that, despite high social vulnerability, surgery is more effective than medical and lifestyle interventions and should be considered in decision-making.

Consultant360: What unanswered questions remain about social determinants of health and metabolic treatment response that clinicians should watch for in future research?

Dr. Patti: Future research to identify optimal but individualized strategies for diabetes care – and incorporating social determinants of health metrics - will be essential. This is even more important given increasing number of effective options available for diabetes control, including both medications and surgery.    

©2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Consultant360 or HMP Global, their employees, and affiliates.